Table 4.

The association of lagged time-dependent statin and survival stratified by demographic and clinical variables

VariablesCategoryAdjusted HR (95% CI)P value for HRPinteraction
Age0.84
65–740.90 (0.66–1.22)0.49
75–840.98 (0.71–1.34)0.88
85+1.18 (0.53–2.62)0.69
Grade0.40
1 or 20.90 (0.63–1.28)0.55
3 or 40.52 (0.22–1.22)0.13
Tumor size and stage1.00
Stage I, <5 cm0.90 (0.60–1.37)0.63
Stage II, <5 cm1.00 (0.61–1.65)0.99
Stage I/II, ≥5 cm1.05 (0.77–1.43)0.77
Resection0.66
No0.97 (0.78–1.20)0.76
Yes0.99 (0.47–2.10)0.98
CVD before cancer diagnosis0.86
No0.92 (0.68–1.26)0.61
Yes0.92 (0.70–1.22)0.57
Cirrhosis0.32
No1.12 (0.86–1.46)0.41
Yes0.87 (0.63–1.20)0.40
Obesity/morbid obesity0.95
Non obese0.99 (0.80–1.21)0.89
Obese0.77 (0.32–1.86)0.57
Dyslipidemia0.41
No0.81 (0.57–1.16)0.25
Yes1.12 (0.87–1.44)0.39
Hepatitis B0.75
No0.98 (0.80–1.22)0.86
Yes0.92 (0.33–2.53)0.87
Hepatitis C0.11
No0.92 (0.73–1.15)0.45
Yes1.26 (0.82–1.93)0.29

Abbreviations: CI, confidence interval; HR, hazard ratio for statin use.